Marcelo Diaz-Bustamante

Marcelo Diaz-Bustamante

Auto-generated profile, based on publicly available information

Marcelo Diaz-Bustamante

Department of Physiology

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2008 in Journal of Comparative Physiology A
Verified
Journal Article
Closed access
PDF file
GHGonzalo Herrera
Gonzalo Herrera
JZJuan Cristóbal Zagal
Juan Cristóbal Zagal
MDMarcelo Diaz
Marcelo Diaz
MFMaria José Fernández
Maria José Fernández
AVAlex Vielma
Alex Vielma
APAdrián G. Palacios
Adrián G. Palacios

22 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
JSJuan Salvatierra
Juan Salvatierra
MDMarcelo Diaz-Bustamante
Marcelo Diaz-Bustamante
JMJames Meixiong
James Meixiong
ETElaine Tierney
Elaine Tierney
XDXinzhong Dong
Xinzhong Dong
FBFrank Bosmans
Frank Bosmans
Itch (pruritis) and pain represent two distinct sensory modalities; yet both have evolved to alert us to potentially harmful external stimuli. Compared with pain, our understanding of itch is still nascent. Here, we report a new clinical case of debilitating itch and altered pain perception resulting from the heterozygous de novo p.L811P gain-of-function mutation in NaV1.9, a voltage-gated sodium (NaV) channel subtype that relays sensory information from the periphery to the spine. To investigate the role of NaV1.9 in itch, we developed a mouse line in which the channel is N-terminally tagged with a fluorescent protein, thereby enabling the reliable identification and biophysical characterization of NaV1.9-expressing neurons. We also assessed NaV1.9 involvement in itch by using a newly created NaV1.9-/- and NaV1.9L799P/WT mouse model. We found that NaV1.9 is expressed in a subset of nonmyelinated, nonpeptidergic small-diameter dorsal root ganglia (DRGs). In WT DRGs, but not those of NaV1.9-/- mice, pruritogens altered action potential parameters and NaV channel gating properties. Additionally, NaV1.9-/- mice exhibited a strong reduction in acute scratching behavior in response to pruritogens, whereas NaV1.9L799P/WT mice displayed increased spontaneous scratching. Altogether, our data suggest an important contribution of NaV1.9 to itch signaling.

9 February 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JRJean-Pierre Rosso
Jean-Pierre Rosso
JSJürgen R. Schwarz
Jürgen R. Schwarz
MDMarcelo Diaz-Bustamante
Marcelo Diaz-Bustamante
BCBrigitte Céard
Brigitte Céard
José María GutiérrezJosé María Gutiérrez
José María Gutiérrez
PBPierre E. Bougis
Pierre E. Bougis
Significance: In this study, we report the identification of the first potent GABAAreceptor-targeting toxins, to our knowledge, in snake venom, which provides a conceptual example for discovering novel ligands to study this receptor family, both functionally and structurally. Moreover, successful synthetic and recombinant production of these toxins [micrurotoxin1 (MmTX1) and MmTX2] will be valuable to further enhance their subtype selectivity or potency. In a broader context, both toxins may provide tools to evoke seizures in assays geared toward testing antiepileptic drugs or as lead molecules for designing therapeutics that modulate GABAAreceptor activity.

31 March 2014 in ACS Chemical Biology
Verified
Journal Article
Open access
JGJohn Gilchrist
John Gilchrist
SDStacey Dutton
Stacey Dutton
MDMarcelo Diaz-Bustamante
Marcelo Diaz-Bustamante
AMAnnie McPherson
Annie McPherson
NONicolas Olivares
Nicolas Olivares
FBFrank Bosmans
Frank Bosmans
Here, we report the discovery of a novel anticonvulsant drug with a molecular organization based on the unique scaffold of rufinamide, an anti-epileptic compound used in a clinical setting to treat severe epilepsy disorders such as Lennox-Gastaut syndrome. Although accumulating evidence supports a working mechanism through voltage-gated sodium (Nav) channels, we found that a clinically relevant rufinamide concentration inhibits human (h)Nav1.1 activation, a distinct working mechanism among anticonvulsants and a feature worth exploring for treating a growing number of debilitating disorders involving hNav1.1. Subsequent structure–activity relationship experiments with related N-benzyl triazole compounds on four brain hNav channel isoforms revealed a novel drug variant that (1) shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6; (2) increases the threshold to action potential initiation in hippocampal neurons; and (3) greatly reduces the frequency of seizures in three animal models. Altogether, our results provide novel molecular insights into the rational development of Nav channel-targeting molecules based on the unique rufinamide scaffold, an outcome that may be exploited to design drugs for treating disorders involving particular Nav channel isoforms while limiting adverse effects.

1 January 2015 in Biophysical Journal
Verified
Journal Article
Closed access
JRJean-Pierre Rosso
Jean-Pierre Rosso
JSJürgen R. Schwarz
Jürgen R. Schwarz
MDMarcelo Diaz-Bustamante
Marcelo Diaz-Bustamante
BCBrigitte Céard
Brigitte Céard
Rolando Ulloa-GutierrezRolando Ulloa-Gutierrez
Rolando Ulloa-Gutierrez
PBPierre E. Bougis
Pierre E. Bougis